Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR in advanced or metastatic NSCLC: a meta-analysis of RCTs.

Front Immunol · 2026 · PMC13287054 · PMID 42344916

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

did not reach statistical significanceP = 0.055so close (0.05 < p ≤ 0.1)

However, in the PD-L1 TPS≥50% subgroup, the OS result did not reach statistical significance (HR = 0.77, 95%CI: 0.59-1.01, P = 0.055).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.